Skip to main content
TipRanks
Go Ultimate75% OFF

James Schutz Insider Profile

4 Followers

James Schutz, Former CEO and Former Director at Sonoma Pharmaceuticals, holds 35.86K shares in Sonoma Pharmaceuticals (Ticker: SNOA). Most recently, James Schutz Bought 2,473 shares of Sonoma Pharmaceuticals on Mar 08, 2018 for an estimated value of $9.87K.

James Schutz's Trading History

SNOA
Sonoma Pharmaceuticals
Mar 08, 2018Former CEO and Former DirectorInformative Buy9.87K$31.56K
SNOA
Insider Shares: 35.86K (0.55%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Mar 08, 2018Informative Buy$9.87K2,473$3.99-75.70%
Jan 03, 2018Uninformative Buy$0.0017,211$0.00―
Dec 04, 2017Informative Buy$1.71K345$4.95-84.10%
Nov 29, 2017Informative Buy$2.01K400$5.03-83.40%
Nov 27, 2017Informative Buy$1.28K254$5.05-84.20%

You May Also Like

James Schutz insider profile FAQ

What is the percentage of profitable transactions made by James Schutz?
The percentage of profitable transactions made by James Schutz is 20%.
What is the average return per transaction made by James Schutz?
The average return per transaction made by James Schutz is -36.90%.
What stocks does James Schutz hold?
James Schutz holds: SNOA stocks.
What was James Schutz’s latest transaction?
James Schutz’s latest transaction was an Informative Buy of $9.87K.
What was James Schutz's most profitable transaction?
James Schutz’s most profitable transaction was an Informative Buy of SNOA stock on August 16, 2016. The return on the trade was 48.50%.
What is James Schutz's role in Sonoma Pharmaceuticals?
James Schutz's role in Sonoma Pharmaceuticals is Former CEO and Former Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.